Naturapharma Ltd Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 08795060

Naturapharma Ltd

Filleted Unaudited Financial Statements

For the year ended

28 February 2025

Naturapharma Ltd

Statement of Financial Position

28 February 2025

	2025	2024
Note	£	£

Fixed assets

Tangible assets	5	39,450	41,049

Current assets

Stocks		120,418	132,151
Debtors	6	1,837,563	1,030,556
Cash at bank and in hand		1,302,433	1,411,035
		------------	------------
		3,260,414	2,573,742

Creditors: amounts falling due within one year	7	3,314,216	2,614,237
		------------	------------
Net current liabilities		53,802	40,495
		--------	--------
Total assets less current liabilities		( 14,352)	554
		--------	----
Net (liabilities)/assets		( 14,352)	554
		--------	----

Capital and reserves

Called up share capital	100	100
Profit and loss account	( 14,452)	454
	--------	----
Shareholders (deficit)/funds	( 14,352)	554
	--------	----

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Naturapharma Ltd

Statement of Financial Position (continued)

28 February 2025

These financial statements were approved by the board of directors and authorised for issue on 17 November 2025 , and are signed on behalf of the board by:

Mr Z Jin

Director

Company registration number: 08795060

Naturapharma Ltd

Notes to the Financial Statements

Year ended 28 February 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 124 City Road, London, EC1V 2NX.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Motor vehicles	-	25% reducing balance
Equipment	-	25% reducing balance

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 2 (2024: 2 ).

5. Tangible assets

	Motor vehicles	Equipment	Total
	£	£	£
Cost
At 1 March 2024	32,668	19,752	52,420
Additions	–	10,361	10,361
Disposals	–	( 1,083)	( 1,083)
	--------	--------	--------
At 28 February 2025	32,668	29,030	61,698
	--------	--------	--------
Depreciation
At 1 March 2024	3,403	7,968	11,371
Charge for the year	7,316	3,964	11,280
Disposals	–	( 403)	( 403)
	--------	--------	--------
At 28 February 2025	10,719	11,529	22,248
	--------	--------	--------
Carrying amount
At 28 February 2025	21,949	17,501	39,450
	--------	--------	--------
At 29 February 2024	29,265	11,784	41,049
	--------	--------	--------

6. Debtors

	2025	2024
	£	£
Trade debtors	1,802,394	986,885
Other debtors	35,169	43,671
	------------	------------
	1,837,563	1,030,556
	------------	------------

7. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	3,235,809	2,548,621
Corporation tax	74,223	61,437
Social security and other taxes	2,509	2,539
Other creditors	1,675	1,640
	------------	------------
	3,314,216	2,614,237
	------------	------------

8. Directors' advances, credits and guarantees

During the year the directors entered into the following advances and credits with the company:

	2025
	Balance brought forward	Advances/ (credits) to the directors	Amounts repaid	Balance outstanding
	£	£	£	£
Mr Z Jin	21,734	95,651	( 100,000)	17,385
Mrs Q Jin	21,735	95,650	( 100,000)	17,385
	--------	---------	---------	--------
	43,469	191,301	( 200,000)	34,770
	--------	---------	---------	--------

	2024
	Balance brought forward	Advances/ (credits) to the directors	Amounts repaid	Balance outstanding
	£	£	£	£
Mr Z Jin	( 806)	142,540	( 120,000)	21,734
Mrs Q Jin	( 805)	142,540	( 120,000)	21,735
	-------	---------	---------	--------
	( 1,611)	285,080	( 240,000)	43,469
	-------	---------	---------	--------